Quadruple Therapy Proves Cost-Effective for First-Line Heart Failure Treatment
A new cost-effectiveness analysis published in *Heart* provides robust evidence for a paradigm shift in managing chronic heart failure with reduced ejection fraction (HFrEF). The study, modeling the NHS perspective, compared five first-line pharmacotherapy combinations. It found that initiating a quadruple regimen—combining an ACE inhibitor (or ARB), beta-blocker, mineralocorticoid receptor antagonist, and an SGLT2 inhibitor—is the most cost-effective strategy for patients who tolerate ACE inhibitors, with an incremental cost-effectiveness ratio of £7,699 per quality-adjusted life-year gained. For those intolerant to ACE inhibitors, a quadruple combination starting with an angiotensin receptor-neprilysin inhibitor (ARNI) was most cost-effective. This analysis challenges the traditional stepwise approach, suggesting that early, aggressive combination therapy optimizes both patient outcomes and healthcare resource use in cardiovascular disease management.
Study Significance: This research offers a critical economic rationale for updating clinical guidelines to recommend quadruple therapy as first-line treatment for HFrEF. For cardiologists and healthcare systems, it provides a data-driven framework to improve survival and reduce hospitalizations while managing budgets effectively. Adopting this strategy could lead to significant improvements in long-term cardiac remodeling and patient quality of life, directly impacting standard care protocols for heart failure and myocardial infarction survivors.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
